CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
作者： S. McNeely , R. Beckmann , A.K. Bence Lin
DOI: 10.1016/J.PHARMTHERA.2013.10.005
关键词:
摘要: … of CHK1 facilitate progression through an unperturbed cell cycle, CHK1 inhibitors are being … This review is intended to provide information on the current progress of CHK1 inhibitors in …
elsevier.com
sci-hub.se 参考文章(106)
Makiko Shimizu, Tadakazu Akiyama, Tetsuya Tsujita, Masami Okabe, Tamio Mizukami, Tetsuo Yoshida, Shiro Akinaga, G1 Phase Accumulation Induced by UCN-01 Is Associated with Dephosphorylation of Rb and CDK2 Proteins as well as Induction of CDK Inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated Human Epidermoid Carcinoma A431 Cells Cancer Research. ,vol. 57, pp. 1495- 1501 ,(1997)
Lin Tang, Paul Dent, Yun Dai, Victor Singh, Robert McInistry, Chunrong Yu, Zhiliang Wang, Steven Grant, Pharmacological Inhibitors of the Mitogen-activated Protein Kinase (MAPK) Kinase/MAPK Cascade Interact Synergistically with UCN-01 to Induce Mitochondrial Dysfunction and Apoptosis in Human Leukemia Cells Cancer Research. ,vol. 61, pp. 5106- 5115 ,(2001)
Ruth Thompson, Alan Eastman, The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. British Journal of Clinical Pharmacology. ,vol. 76, pp. 358- 369 ,(2013) , 10.1111/BCP.12139
William R Taylor, George R Stark, Regulation of the G2/M transition by p53 Oncogene. ,vol. 20, pp. 1803- 1815 ,(2001) , 10.1038/SJ.ONC.1204252
David Cortez, Saritha Guntuku, Jun Qin, Stephen J Elledge, ATR and ATRIP: Partners in Checkpoint Signaling Science. ,vol. 294, pp. 1713- 1716 ,(2001) , 10.1126/SCIENCE.1065521
Christopher Bryant, Rebecca Rawlinson, Andrew J Massey, Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers BMC Cancer. ,vol. 14, pp. 570- 570 ,(2014) , 10.1186/1471-2407-14-570
Susan Ashwell, James W Janetka, Sonya Z abludoff, Keeping checkpoint kinases in line: new selective inhibitors in clinical trials Expert Opinion on Investigational Drugs. ,vol. 17, pp. 1331- 1340 ,(2008) , 10.1517/13543784.17.9.1331
Yan Luo, Shayna K. Rockow-Magnone, Paul E. Kroeger, Leigh Frost, Zehan Chen, Edward K.-H. Han, Shi-Chung Ng, Robert L. Simmer, Vincent L. Giranda, Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. Neoplasia. ,vol. 3, pp. 411- 419 ,(2001) , 10.1038/SJ.NEO.7900175
S. Delacroix, J. M. Wagner, M. Kobayashi, K.-i. Yamamoto, L. M. Karnitz, The Rad9–Hus1–Rad1 (9–1–1) clamp activates checkpoint signaling via TopBP1 Genes & Development. ,vol. 21, pp. 1472- 1477 ,(2007) , 10.1101/GAD.1547007
Yun Dai, Shuang Chen, Xin-Yan Pei, Jorge A. Almenara, Lora B. Kramer, Charis A. Venditti, Paul Dent, Steven Grant, Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood. ,vol. 112, pp. 2439- 2449 ,(2008) , 10.1182/BLOOD-2008-05-159392